Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy
Journal of Clinical Medicine · 23.09.2023 · 12 (19) · 6141
DOI: 10.3390/jcm12196141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.09.2023. Verfasst von Esteban Sánchez-Toscano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Andalusian Endocrinology and Nutrition Society (SAEDYN).
Abstract (Originalsprache)
Introduction
In the last decade, healthcare for the transgender population has increased considerably in many countries thanks to depathologization movements and the easier accessibility of medical assistance. The age at which they request to start gender-affirming hormones (GAHs) is increasingly younger. The cardiovascular risk associated with hormonal treatment is a novel research field, and the published studies are heterogeneous and inconclusive. Our objective is to determine the metabolic impact of GAHs in the transgender people treated in our Gender Identity Treatment Unit.
Methods
We designed a pre–post study to analyze changes in anthropometric parameters (weight and body mass index), analytical determinations (fasting blood glucose, glycated hemoglobin, and lipoproteins), and blood pressure control in the transgender population treated with GAHs in Puerta del Mar University Hospital. These variables were collected before and one year after hormonal therapy.
Results
A total of 227 transgender people were recruited between 2017 and 2020, 97 (40.09%) transwomen and 136 (59.91%) transmen. The average age at which GAHs began was 18 years. Weight, body mass index, and blood pressure increased significantly in both genders. Transmen showed a more atherogenic lipid profile, with a decrease in cholesterol LDL (p < 0.001) and an increase in triglycerides (p < 0.001). The risk of developing prediabetes or diabetes did not increase one year after treatment, although non-specific alterations in carbohydrate metabolism were detected, such as an increase in glycated hemoglobin in transmen (p = 0.040) and fasting blood glucose in transwomen (p = 0.008). No thromboembolic processes or cardiovascular events were reported during the first year of treatment.
Conclusion
In our setting, transgender people developed changes in their metabolic profiles in the first year after hormonal treatment. Both transmen and transwomen showed early alterations in lipid and carbohydrate metabolism, slight elevations in blood pressure, and a tendency to gain weight. This makes lifestyle interventions necessary from the beginning of GAHs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology and Nutrition Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain.
- Biomedical Research and Innovation Institute of Cádiz (INiBICA), 11009 Cádiz, Spain.
- Pediatrics and Specific Areas Department, Puerta del Mar University Hospital, 11009 Cádiz, Spain.
- School of Medicine, Cadiz University (UCA), 11003 Cádiz, Spain.
ORCID-Profile: Esteban Sánchez-Toscano, Jesús Domínguez-Riscart, Manuel Aguilar-Diosdado
Förderung
- Andalusian Endocrinology and Nutrition Society (SAEDYN)
Zitieren
APA
Sánchez-Toscano, E., Domínguez-Riscart, J., Larrán-Escandón, L., Mateo-Gavira, I., & Aguilar-Diosdado, M. (2023). Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy. Journal of Clinical Medicine, 12(19), 6141. https://doi.org/10.3390/jcm12196141
Vancouver
Sánchez-Toscano E, Domínguez-Riscart J, Larrán-Escandón L, Mateo-Gavira I, Aguilar-Diosdado M. Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy. Journal of Clinical Medicine. 2023;12(19):6141. doi:10.3390/jcm12196141
BibTeX
@article{SnchezToscano2023,
author = {Sánchez-Toscano, Esteban and Domínguez-Riscart, Jesús and Larrán-Escandón, Laura and Mateo-Gavira, Isabel and Aguilar-Diosdado, Manuel},
title = {Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {19},
pages = {6141},
doi = {10.3390/jcm12196141}
}
EUVIMED